Home
Recent press, briefings and insights helping you stay informed on AliveDx newest launch.
Eysins, 6 November 2023 — AliveDx a global in vitro diagnostics company headquartered in Eysins, Switzerland, today announced it has now received IVDR Certification for both its state-of-the-art manufacturing facilities located in Eysins, Switzerland and Edinburgh, United Kingdom. AliveDx is
AliveDx receives three IVDR CE Marks for its automated, multiplexed MosaiQ® solution, enabling faster diagnosis of Connective Tissue Diseases (CTD). Eysins, 30 October 2023 — AliveDx is proud to announce it has received three CE Marks for: Its MosaiQ Centromere Protein B (CENP-B)
JERSEY, Channel Islands, September 8th 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient), headquartered in Eysins, Switzerland, today announced it was selected by the World Economic Forum to join their New Champions Community. “We are delighted
JERSEY, Channel Islands, 24 August 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient), headquartered in Eysins, Switzerland, today announced the National Screening Laboratory of Sanquin Blood Supply Foundation, Department Research & Labservices (Sanquin), headquartered in Amsterdam,
JERSEY, Channel Islands, June 8, 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced an agreement with Theradiag, a market leader in autoimmune disease testing and pioneer in theranostics, under which the two companies will partner
Diversified global presence key to Company’s go-to-market strategy Strengthened geographical expansion with distributor strategy model to better support customers in the region JERSEY, Channel Islands, May 17, 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company,
JERSEY, Channel Islands, May 12, 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that it will host a key opinion leader (KOL) webinar on the current landscape and unmet needs within blood grouping and
New York Blood Center, Inc. and Centro de Transfusiones de la Comunidad de Madrid join MosaiQ’s Innovator’s Circle in partnership to improve patient care and laboratory efficiencies JERSEY, Channel Islands, 21 March 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a
The Extended Immunohematology microarray provides labs with comprehensive characterization, simplified workflow, and high throughput—all on a single multimodal multiplexing platform JERSEY, Channel Islands, 8 March 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered
MosaiQ virtual Scientific Advisory Board (SAB) was attended this week by eight Key Opinion Leaders (KOLs) from the US and various European countries Quotient’s focus is to strengthen MosaiQ scientific and medical evidence through the Innovator’s Circle and Investigator Initiated